LRRK2 INHIBITORS

Patent Number: TW-202330549-A

Publication Year: 2023

Application Year: 2022

Priority Year: 2021

Jurisdictions: TW

Status: N/A

Inventors:

CHRISTOPHER RICHARD JONES JENSEN THOMAS JENSEN THOMAS JENSEN THOMAS JENSEN THOMAS JENSEN THOMAS JENSEN THOMAS JENSEN THOMAS JENSEN THOMAS JENSEN THOMAS DAVID RODRIGUEZ DIAZ JESSING MIKKEL JESSING MIKKEL JESSING MIKKEL JESSING MIKKEL JESSING MIKKEL JESSING MIKKEL JESSING MIKKEL JESSING MIKKEL JESSING MIKKEL NIELSEN JACOB YU WAN-WAN YU WANWAN YU WANWAN YU WANWAN YU WANWAN YU WANWAN YU WANWAN YU WANWAN YU WANWAN DIAZ DAVID RODRIGUEZ DIAZ DAVID RODRIGUEZ DIAZ DAVID RODRIGUEZ DIAZ DAVID RODRIGUEZ DIAZ DAVID RODRIGUEZ DIAZ DAVID RODRIGUEZ DIAZ DAVID RODRIGUEZ DIAZ DAVID RODRIGUEZ MIKKEL FOG JACOBSEN RODRIGUEZ DIAZ DAVID JESSING MIKKEL NIELSEN JACOB NIELSEN JACOB NIELSEN JACOB NIELSEN JACOB NIELSEN JACOB NIELSEN JACOB NIELSEN JACOB NIELSEN JACOB NIELSEN JACOB ANDERSEN THOMAS JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD JONES CHRISTOPHER RICHARD ANDERSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS ANDERSEN THOMAS JENSEN THOMAS JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG JACOBSEN MIKKEL FOG YU WANWAN

Applicants:

  1. Lundbeck (Denmark)
    2. [NORA names: Lundbeck; Private Research; Denmark; Europe, EU; Nordic; OECD]
  2. Ligand Pharmaceuticals (United Kingdom)
    3. [NORA names: United Kingdom; Europe, Non-EU; OECD]

Abstract

The present invention is directed to compounds of formula I

embedded image

The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

Patent Family Records (10)

LRRK2 inhibitors  

H Lundbeck AS, Lundbeck (Denmark) JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2024, US-11993612-B2

LRRK2 INHIBITORS  

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD CHRISTOPHER RICHARD JONES, DAVID RODRIGUEZ DIAZ, NIELSEN JACOB, (...more)

2024, BR-112023012947-A2

LRRK2 INHIBITORS  

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2024, AR-127470-A1

LRRK2 INHIBITORS  

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2023, WO-2023073013-A9

LRRK2 INHIBITORS  

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2023, WO-2023073013-A8

LRRK2 INHIBITORS  

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2023, WO-2023073013-A1

LRRK2 INHIBITORS  

H Lundbeck AS, Lundbeck (Denmark) JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2023, US-20230416272-A1

LRRK2 INHIBITORS  

H Lundbeck AS, Lundbeck (Denmark) JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2023, US-20230144725-A1

LRRK2 inhibitors  

H Lundbeck AS, Lundbeck (Denmark) JENSEN THOMAS, JESSING MIKKEL, YU WANWAN, (...more)

2023, US-11780851-B2

LRRK2 INHIBITORS

H LUNDBECK AS, Ligand Pharmaceuticals (United Kingdom), Lundbeck (Denmark), VERNALIS R&D LTD JENSEN THOMAS, JESSING MIKKEL, YU WAN-WAN, (...more)

2023, TW-202330549-A

Data Provider: Digital Science

LINKS
+

External Systems

SUBJECTS
+

PATENT CATEGORIES
+

METRICS
+

Citation Metrics

Times Cited in Patents: 0external link

References to Patents: [No Data Available]

References to Publications: 0external link